blarcamesine

Small moleculeexperimental

Clinical trial activity

9 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
6
Phase 3
3
Phase 4
0

Earliest trial started Dec 1, 2014 (NCT02244541)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CC1CCOC1(c1ccccc1)c1ccccc1
Mol. weight
281.4 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • anavex2-73
  • anavex2-73
  • anavex2-73
  • tetrahydro-n, n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04304482Phase 2/Phase 3 (Phase 3)Apr 30, 2020Anavex Life Sciences Corp.
NCT04575259Phase 2Oct 10, 2019Anavex Life Sciences Corp.
NCT04314934Phase 2/Phase 3 (Phase 3)Oct 10, 2019Anavex Life Sciences Corp.
NCT03941444Phase 2May 6, 2019Anavex Life Sciences Corp.
NCT03758924Phase 2Feb 28, 2019Anavex Life Sciences Corp., Emory University, International Rett Syndrome Foundation
NCT03774459Phase 2Jul 9, 2018Anavex Life Sciences Corp.
NCT03790709Phase 2/Phase 3 (Phase 3)Jul 3, 2018Anavex Life Sciences Corp.
NCT02756858Phase 2Mar 1, 2016Anavex Life Sciences Corp.
NCT02244541Phase 2Dec 1, 2014Anavex Life Sciences Corp., Caulfield Hospital
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Anavex Life Sciences Corp.For profit9922014
Caulfield HospitalAcademic/Hospital1012014
Emory UniversityAcademic/Hospital1012019
International Rett Syndrome FoundationAcademic/Hospital1012019
4 organizations
Page 1 / 1